retatrutide phase 2 trial type 2 diabetes Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, conducted in the USA A New Obesity Drug Delivered
Pay in 4 interest-free payments of $5.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7

















01751-7/asset/3ca38b3a-c38f-46d7-97dd-3dad8e5acaff/main.assets/gr2a.jpg)





